Cocrystal Pharma, Inc. (FRA:8CC)
Germany · Delayed Price · Currency is EUR | Market Cap | 12.08M -6.2% |
| Revenue (ttm) | 195.14K |
| Net Income | -7.66M |
| EPS | -0.63 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.8450 |
| Previous Close | 0.8400 |
| Day's Range | 0.8450 - 0.8450 |
| 52-Week Range | 0.7050 - 2.8000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About Cocrystal Pharma
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment fo... [Read more]
News
Cocrystal co-CEOs Sam Lee and Jim Martin step down, James Sapirstein succeeds
Cocrystal Pharma (COCP) has appointed James Sapirstein CEO, effective immediately. The company also plans to appoint Sapirstein as a member of the board of directors. Sapirstein replaces Sam Lee and…
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the ...
Cocrystal Pharma announces discovery of pan-viral inhibitors targeting viruses
Cocrystal Pharma (COCP) announces that its novel direct-acting antivirals demonstrate pan-viral activity against multiple viruses, including hantavirus, bunyavirus and influenza. These antiviral molec...
Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza
Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influenza Hantavirus and bunyavirus infections represen...
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
BOTHELL, Wash., May 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides updates on its antiviral product pipeline and business activities and rep...
Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
BOTHELL, Wash., April 30, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the mechanism of action and clinical advancement of its first ora...
Cocrystal Pharma files $150M mixed securities shelf
19:24 EDT Cocrystal Pharma (COCP) files $150M mixed securities shelf
Cocrystal Pharma receives FDA Fast Track designation for CDI-988
Cocrystal Pharma (COCP) announced that the FDA has granted Fast Track designation to its oral, direct-acting protease inhibitor, CDI-988, the first oral antiviral candidate being developed for treatme...
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion i...
Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Phase 1b norovirus challenge study is underway at Emory University School of Medicine CDI-988 is the first oral antiviral candidate being developed for norovirus treatment and prevention No approved t...
Cocrystal Pharma announces first subjects dosed in Phase 1b study of CDI-988
Cocrystal Pharma (COCP) announces the first subjects have been dosed in a Phase 1b norovirus challenge study to evaluate CDI-988 as both a preventive and treatment for norovirus infections. This…
First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
CDI-988 is a direct-acting, oral antiviral being developed for norovirus Norovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988 No appr...
Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026
BOTHELL, Wash., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that initial progress of a norovirus challenge study with its direct-ac...
Cocrystal Pharma receives IRB approval from Emory University for Phase 1b trial
Cocrystal Pharma (COCP) announces the approval from the Institutional Review Board, IRB, at Emory University School of Medicine to initiate a Phase 1b human challenge study with CDI-988. This study…
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the approval from the Institutional Review Board (IRB) at Emory Univers...
Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference
BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview and ...
Cocrystal Pharma reports Q3 EPS (19c) vs (49c) last year
“We expect to begin enrolling participants in the first quarter of 2026 for our norovirus challenge study evaluating CDI-988, our oral broad-spectrum protease inhibitor,” said Sam Lee, Ph.D., Presiden...
Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatment Expects to initiate CDI-988 Phase 1b norovirus challenge study in Q1 2026 Granted NIH SBIR award to advance in...
Cocrystal Pharma completes $1.03M private placement
Cocrystal Pharma (COCP) announces the completion of a private placement of units priced at-the-market under Nasdaq rules with 743,024 shares of its common stock at a purchase price of $1.39…
Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
Investment by Directors and Management demonstrates confidence in the Company Potential for an additional $ 1.8 million upon the exercise in full of warrants BOTHELL, Wash., Oct. 30, 2025 (GLOBE NEWSW...
Cocrystal Pharma receives NIH SBIR award to advance influenza inhibitor program
Cocrystal Pharma (COCP) announces it has received a Small Business Innovation Research, SBIR, Phase I award from the National Institutes of Health, NIH, National Institute of Allergy and Infectious Di...
Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.
Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
BOTHELL, Wash., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview at t...
Cocrystal Pharma files to sell 5.74M shares of common stock for holders
16:32 EDT Cocrystal Pharma (COCP) files to sell 5.74M shares of common stock for holders
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants